There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Could a new ADC project distract attention away from evorpacept?
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
